“Abemaciclib Plus Endocrine Therapy Improves Survival in High-Risk Early Breast Cancer: Longer Follow-Up Needed for Certain Efficacy Results”

https://pubmed.ncbi.nlm.nih.gov/38114413

Abemaciclib plus endocrine therapy shows improved invasive disease-free survival in high-risk early breast cancer, but longer follow-up is needed for more certain efficacy results.